MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
6. Technology Transfer (T2), NonDilutive Funding: Strategy Development
* T2ToolBox
Triple Helix: Reports, Publications & Metrics
Triple Helix: Regional Innovation Clusters (RIC)s
Intermediaries: Triple Helix Regional Innovation Clusters (RIC)s
RICS (Regional Innovation Clusters) - Medical, Life Sciences & Emerging Technology Hotspots
*Industry: Ireland
Ipsen SA (OTC: IPSEY)
Organization & Developments: Ipsen
Parents
Ipsen SA (OTC: IPSEY)
Children
*BioMerieux is also in a partnership with pharmaceutical firm Ipsen (PARIS:IPN) to develop companion diagnostics for cancer, tests that help doctors make therapeutic decisions about how to treat patients and which drugs to use.
*Endocrinology
*Ipsen focuses on three targeted specialty care areas
*Ipsen operates throughout the entire value chain, from research through to marketing.
*Neurology
*R&D expenditure close to €250 million representing more than 20% of sales
*Sales of more than €1.2 billion in 2012
*Tercica
*Urology-oncology
2022: Ipsen S.A. 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2023: Ipsen's Onivyde proves its worth in aggressive pancreatic cance
2024: Ipsen Inks Potential $900M Deal with Sutro for Global Rights to Preclinical ADC
2024: Ipsen joins ADC race via $900M biobuck deal with Sutro, chasing same target as Merck, Boehringer
Jumps
*Key People: Ipsen
Finance & Acquisitions: Ipsen